17A-hydroxyprogesterone hexanoate

Independent reference data for 17A-hydroxyprogesterone hexanoate (CAS 630-56-8), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Pharmaceuticals -> Animal Drugs -> Approved in TaiwanHydroxyprogesterone caproate was previously indicated in the US for the prevention of spontaneous preterm births in singleton pregnancies in women with a history of spontaneous preterm birth. This indication was revoked by the FDA in April 2023. Hydroxyprogesterone caproate remains indicated in other jurisdictions for the management of primary and secondary amenorrhea, corpus luteum insufficiency, and for the prevention of preterm birth.

Synonyms and trade names

HYDROXYPROGESTERONE CAPROATE; 630-56-8; Delalutin; Primolut Depot; Hydroxyprogesterone hexanoate; Hormofort; Syngynon; Proluton Depot; Depo-Proluton; Teralutil; Hylutin; Makena; Pharlon; 17alpha-Hydroxyprogesterone caproate; Procyte depo; NSC-17592

GHS hazard classification

Reported hazard statements	H360 (93.2%)

H360 (93.2%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

What the public record says

17A-hydroxyprogesterone hexanoate · CAS 630-56-8 · C27H40O4. UNII 276F2O42F5. Melting Point: 119-121.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.